search
Back to results

Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin (PD-497314)

Primary Purpose

Venous Leg Ulcer

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Exufiber Gelling Fibre Dressing
Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre
Sponsored by
Molnlycke Health Care AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Venous Leg Ulcer focused on measuring wound reduction wound healing, venous ulcers

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Provision of informed consent i.e. subject must be able to understand and sign the Patient Information and Consent Form
  2. Both gender ≥18 years old
  3. Ulcer moderately or strongly exudative justifying the use of an absorbent dressing
  4. (History of compression at least two weeks before inclusion) Deleted in Am.2
  5. (Wound covered with slough ≥70%) Deleted in Am.4
  6. 0.7≤ABPI<1.3
  7. Ulcer duration 6 weeks to 60 months
  8. Ulcer size 3 cm2-100 cm2
  9. Target ulcer at least 3 cm away from any other lesion

Exclusion Criteria:

  1. Known allergy/hypersensitivity to the dressings
  2. Pregnant or breastfeeding
  3. Circumferential wounds (the entire wound should be able to be captured on a single image/photo)
  4. Subjects who will have problems following the protocol
  5. Subjects included in other ongoing clinical investigation evaluating wound dressings at present or during the past 30 days
  6. Patient with a systemic infection not controlled by suitable antibiotic treatment
  7. Clinically infected wound according to the judgement of the investigator (heat, pain, swelling, redness or purulent secretion)
  8. Wound covered with black necrosis
  9. Dry wounds
  10. Malignant wound degeneration
  11. Current treatment with radiotherapy, chemotherapy, immunosuppressant drugs or high doses of oral corticosteroids if any
  12. Subject with deep vein thrombosis within 3 months prior to inclusion

Sites / Locations

  • St. Ann University Hospital Dep of Dermatovenereology
  • Hospital Jihlava
  • Regional hospital Pardubice Dermatology Department
  • Fakultní nemocnice Královské Vinohrady (FNKV)Department of General Surgery 3
  • General University Hospital in Prague
  • Diabetologie
  • Salvatella LTD
  • Bispebjerg Hospital
  • Hôpital Michallon
  • Groupe Hospitalier
  • Hospital Géneral du Mans
  • Clinique du Parc Unité de Cicatrisation
  • CHU Nantes
  • Clinique Pasteur
  • Wundzentrum Augsburg
  • WundZentrum Dortmund
  • WundZentrum Düsseldorf
  • Universitätsklinikum Erlangen
  • Venenzentrum Freiburg
  • Paracelsus-Klinik am Silbersee
  • University Hospital Schleswig-Holstein
  • Johannes-Gutenberg-Universität Mainz
  • WundZentrum München Nord
  • WundZentrum Ulm
  • Usługi Medyczne PRO-MED Sp. z o.o., ul.
  • Niepubliczny Zakład Opieki Zdrowotnej "GAM-MED", ul.
  • Medical Hair & Esthetic, ul.
  • Niepubliczny Zakład Opieki Zdrowotnej "Mikomed", ul.
  • Lund university Hospital,
  • Skellefteå Lasarett
  • Karolinska Trial Alliance, Prim
  • Södersjukhuset (Sårcentrum)
  • Avdelningen för kliniska prövningar, Universitetssjukhuset Örebro

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Dressing Exufiber®Gelling Fibre Dressing

Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin

Arm Description

will receive dressing Exufiber®

Will receive Aquacel®Extra™

Outcomes

Primary Outcome Measures

Wound Area Change (%)
The primary endpoint was to measure relative reduction of wound area (%) from baseline to end of investigation (up to 6 weeks measured by the validated system PictZar on the photos taken after debridement at week 0, week 4, and week 6 (or final visit if healed earlier)

Secondary Outcome Measures

Wound Area Change (cm2)
The secondary endpoint was to measure relative reduction of wound area (cm2) from baseline to end of investigation (up to 6 weeks measured by the validated system PictZar on the photos taken after debridement at week 0, week 4, and week 6 (or final visit if healed earlier)
Linear Advance of Wound Margin
Linear advance of the wound margin according to Gilman's formula (G= [(A0-An) / ((P0+Pn) / 2)] / Time) was calculated and evaluated using the validated system PictZar on the photos taken after debridement. The values represent wound margin advanced inwards over time (i.e., reduction in perimeter) presented in cm/day.
Pain During Debridement
Pain was reported by patients and measured by Visual Analogue Scale (VAS) 0-100mm, where 0=is no pain, 100=is worst pain ever.
Pain at Dressing Removal
Pain was reported by patients and measured by Visual Analogue Scale (VAS) 0-100mm, where 0=is no pain, 100=is worst pain ever.
Percentage of Clinicians of Opinion 'Very Good' for Dressing Features
Clinician reported outcomed by means a questionnaire was used to capture opinions related to the two dressing types. Reply alternatives varied between very poor, poor, good, very good. Results reported as 'very good' are presented as a percentage based on all follow-up visits aggregated.
Percentage of Clinicians of Opinion 'Does Not Adhere' Related to Dressing Features
Clinician reported outcomed by means a questionnaire was used to capture opinions related to the two dressing types. Reply alternatives varied between does not adhere, adhere a little, adhere a lot. Results reported as 'does not adhere' are presented as a percentage based on all follow-up visits aggregated.

Full Information

First Posted
September 19, 2016
Last Updated
October 8, 2020
Sponsor
Molnlycke Health Care AB
search

1. Study Identification

Unique Protocol Identification Number
NCT02921750
Brief Title
Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin
Acronym
PD-497314
Official Title
A Randomised Multi-centre Non-inferiority Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
October 2016 (Actual)
Primary Completion Date
November 27, 2019 (Actual)
Study Completion Date
November 27, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Molnlycke Health Care AB

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigation is designed as an open, randomized, non-inferiority, multi-centre investigation. 212 evaluable subjects will be randomised. Subjects to be included will suffer from an exuding venous or mixed ulcer of predominantly venous origin. Subjects will either be randomized to Exufiber®Gelling Fibre Dressing or Aquacel®Extra Hydrofiber® Dressing with Strengthening Fibre using, centralized randomization
Detailed Description
Visits are planned for baseline followed by 1, 2, 3, 4 and 6 weeks post treatment. The sub-group of at least 50 subjects will also be followed at week 8, 12, 16, 20, and 24 post treatment or until wound is healed if earlier.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Leg Ulcer
Keywords
wound reduction wound healing, venous ulcers

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
248 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dressing Exufiber®Gelling Fibre Dressing
Arm Type
Experimental
Arm Description
will receive dressing Exufiber®
Arm Title
Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin
Arm Type
Active Comparator
Arm Description
Will receive Aquacel®Extra™
Intervention Type
Device
Intervention Name(s)
Exufiber Gelling Fibre Dressing
Intervention Description
Gelling fibre dressing
Intervention Type
Device
Intervention Name(s)
Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre
Intervention Description
Hydrofiber® Dressing with Strengthening Fibre
Primary Outcome Measure Information:
Title
Wound Area Change (%)
Description
The primary endpoint was to measure relative reduction of wound area (%) from baseline to end of investigation (up to 6 weeks measured by the validated system PictZar on the photos taken after debridement at week 0, week 4, and week 6 (or final visit if healed earlier)
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Wound Area Change (cm2)
Description
The secondary endpoint was to measure relative reduction of wound area (cm2) from baseline to end of investigation (up to 6 weeks measured by the validated system PictZar on the photos taken after debridement at week 0, week 4, and week 6 (or final visit if healed earlier)
Time Frame
6 weeks
Title
Linear Advance of Wound Margin
Description
Linear advance of the wound margin according to Gilman's formula (G= [(A0-An) / ((P0+Pn) / 2)] / Time) was calculated and evaluated using the validated system PictZar on the photos taken after debridement. The values represent wound margin advanced inwards over time (i.e., reduction in perimeter) presented in cm/day.
Time Frame
6 weeks
Title
Pain During Debridement
Description
Pain was reported by patients and measured by Visual Analogue Scale (VAS) 0-100mm, where 0=is no pain, 100=is worst pain ever.
Time Frame
6 weeks
Title
Pain at Dressing Removal
Description
Pain was reported by patients and measured by Visual Analogue Scale (VAS) 0-100mm, where 0=is no pain, 100=is worst pain ever.
Time Frame
6 weeks
Title
Percentage of Clinicians of Opinion 'Very Good' for Dressing Features
Description
Clinician reported outcomed by means a questionnaire was used to capture opinions related to the two dressing types. Reply alternatives varied between very poor, poor, good, very good. Results reported as 'very good' are presented as a percentage based on all follow-up visits aggregated.
Time Frame
6 weeks
Title
Percentage of Clinicians of Opinion 'Does Not Adhere' Related to Dressing Features
Description
Clinician reported outcomed by means a questionnaire was used to capture opinions related to the two dressing types. Reply alternatives varied between does not adhere, adhere a little, adhere a lot. Results reported as 'does not adhere' are presented as a percentage based on all follow-up visits aggregated.
Time Frame
6 weeks
Other Pre-specified Outcome Measures:
Title
Percentage of Participants With Healed Wounds
Description
Wound healing assessments were based on blind independent clinical review of photos.
Time Frame
from baseline to 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provision of informed consent i.e. subject must be able to understand and sign the Patient Information and Consent Form Both gender ≥18 years old Ulcer moderately or strongly exudative justifying the use of an absorbent dressing (History of compression at least two weeks before inclusion) Deleted in Am.2 (Wound covered with slough ≥70%) Deleted in Am.4 0.7≤ABPI<1.3 Ulcer duration 6 weeks to 60 months Ulcer size 3 cm2-100 cm2 Target ulcer at least 3 cm away from any other lesion Exclusion Criteria: Known allergy/hypersensitivity to the dressings Pregnant or breastfeeding Circumferential wounds (the entire wound should be able to be captured on a single image/photo) Subjects who will have problems following the protocol Subjects included in other ongoing clinical investigation evaluating wound dressings at present or during the past 30 days Patient with a systemic infection not controlled by suitable antibiotic treatment Clinically infected wound according to the judgement of the investigator (heat, pain, swelling, redness or purulent secretion) Wound covered with black necrosis Dry wounds Malignant wound degeneration Current treatment with radiotherapy, chemotherapy, immunosuppressant drugs or high doses of oral corticosteroids if any Subject with deep vein thrombosis within 3 months prior to inclusion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bo Joergensen, MD
Organizational Affiliation
Bispebjerg Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Ann University Hospital Dep of Dermatovenereology
City
Brno
ZIP/Postal Code
656 91
Country
Czechia
Facility Name
Hospital Jihlava
City
Jihlava
ZIP/Postal Code
58601
Country
Czechia
Facility Name
Regional hospital Pardubice Dermatology Department
City
Pardubice
ZIP/Postal Code
53203
Country
Czechia
Facility Name
Fakultní nemocnice Královské Vinohrady (FNKV)Department of General Surgery 3
City
Prague
ZIP/Postal Code
10034
Country
Czechia
Facility Name
General University Hospital in Prague
City
Prague
ZIP/Postal Code
128 08
Country
Czechia
Facility Name
Diabetologie
City
Sobeslav
ZIP/Postal Code
39201
Country
Czechia
Facility Name
Salvatella LTD
City
Třinec
ZIP/Postal Code
739 61
Country
Czechia
Facility Name
Bispebjerg Hospital
City
Copenhagen
State/Province
Copenhagen NV
ZIP/Postal Code
2200
Country
Denmark
Facility Name
Hôpital Michallon
City
Grenoble
ZIP/Postal Code
38043
Country
France
Facility Name
Groupe Hospitalier
City
La Rochelle
ZIP/Postal Code
17019
Country
France
Facility Name
Hospital Géneral du Mans
City
Le Mans
ZIP/Postal Code
72000
Country
France
Facility Name
Clinique du Parc Unité de Cicatrisation
City
Lyon
ZIP/Postal Code
69006
Country
France
Facility Name
CHU Nantes
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
Clinique Pasteur
City
Toulouse
ZIP/Postal Code
31076
Country
France
Facility Name
Wundzentrum Augsburg
City
Augsburg
ZIP/Postal Code
86152
Country
Germany
Facility Name
WundZentrum Dortmund
City
Dortmund
ZIP/Postal Code
44137
Country
Germany
Facility Name
WundZentrum Düsseldorf
City
Düsseldorf
Country
Germany
Facility Name
Universitätsklinikum Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Venenzentrum Freiburg
City
Freiburg
ZIP/Postal Code
79008
Country
Germany
Facility Name
Paracelsus-Klinik am Silbersee
City
Hannover
Country
Germany
Facility Name
University Hospital Schleswig-Holstein
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
Johannes-Gutenberg-Universität Mainz
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
WundZentrum München Nord
City
München
ZIP/Postal Code
80939
Country
Germany
Facility Name
WundZentrum Ulm
City
Ulm
ZIP/Postal Code
89077
Country
Germany
Facility Name
Usługi Medyczne PRO-MED Sp. z o.o., ul.
City
Gliwice
ZIP/Postal Code
44-109
Country
Poland
Facility Name
Niepubliczny Zakład Opieki Zdrowotnej "GAM-MED", ul.
City
Kielce
ZIP/Postal Code
25-315
Country
Poland
Facility Name
Medical Hair & Esthetic, ul.
City
Lublin
ZIP/Postal Code
20-844
Country
Poland
Facility Name
Niepubliczny Zakład Opieki Zdrowotnej "Mikomed", ul.
City
Łódź
ZIP/Postal Code
94-238
Country
Poland
Facility Name
Lund university Hospital,
City
Lund
ZIP/Postal Code
22185
Country
Sweden
Facility Name
Skellefteå Lasarett
City
Skellefteå
ZIP/Postal Code
931 41
Country
Sweden
Facility Name
Karolinska Trial Alliance, Prim
City
Stockholm
ZIP/Postal Code
113 61
Country
Sweden
Facility Name
Södersjukhuset (Sårcentrum)
City
Stockholm
ZIP/Postal Code
118 83
Country
Sweden
Facility Name
Avdelningen för kliniska prövningar, Universitetssjukhuset Örebro
City
Örebro
ZIP/Postal Code
70185
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin

We'll reach out to this number within 24 hrs